Voltage-dependent calcium channel Inhibitors
1 drugsAbout Voltage-dependent calcium channel
Voltage-dependent calcium channels (VDCCs) are transmembrane proteins that mediate calcium influx into excitable cells upon membrane depolarization. This influx triggers intracellular processes like muscle contraction, neurotransmitter release, and hormone secretion.
VDCCs are important drug targets, particularly in cardiovascular disease. Currently, there is no genetic evidence data available linking VDCCs to specific diseases.
There is one FDA-approved drug, AZOR (COSETTE), targeting VDCCs for cardiovascular indications. AZOR is a small molecule approved in 2007.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Obesity with only 1 trials.
- phase3 represents biological uncertainty with 57% completion.
Top Voltage-dependent calcium channel Drugs
COSETTE is the only company with an approved drug targeting VDCCs.
The lack of competitors suggests a high barrier to entry or an untapped market opportunity.
Voltage-dependent calcium channel Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Voltage-dependent calcium channel, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Voltage-dependent calcium channel Clinical Trials 110 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 22 | 19 | 1 | 2 | 95% |
| Phase 2 | 15 | 12 | 1 | 2 | 92% |
| Phase 3 | 28 | 21 | 5 | 2 | 81% |
| Phase 4 | 45 | 27 | 10 | 8 | 73% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Voltage-dependent calcium channel Drug Approval Timeline (2007 - 2007)
The first and only drug, AZOR, was approved in 2007.
The absence of recent approvals indicates potential saturation or a need for innovative approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 62 clinical trials targeting Voltage-dependent calcium channel.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities